Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809783 · ClinicalTrials.gov registry record · Phase 3
Extension Study Of Tanezumab In Osteoarthritis
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,147
- Enrollment target
NCT00809783: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00809783 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2,147 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (178% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00809783, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,147 participants
- Enrollment target
Study Summary
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
Primary Outcome
AE:any untoward medical occurrence in participant who received study medication without regard to possibility of causal relationship. SAE:an AE resulting in any of following outcomes or deemed significant for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience(immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly. Treatment-emergent are events between first dose of study medication and up to 112 days after last d
Interventions
- BIOLOGICAL tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,147 participants |
| Start Date | 2009-02-06 |
| Est. Completion | 2011-06-23 |
| Phase | Phase 3 |
Why NCT00809783 stopped before completion
NCT00809783 is an interventional study that assigns participants to a tested intervention. Its 2,147 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (178% higher).
The record links to 0 conditions, and to 1 intervention - of which tanezumab is the first listed.
NCT00809783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00809783 about?
NCT00809783 is a clinical study titled "Extension Study Of Tanezumab In Osteoarthritis". Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
What is the current status of trial NCT00809783?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,147 participants. The study started on 2009-02-06. Estimated completion is 2011-06-23.
What interventions are being tested in trial NCT00809783?
The interventions under investigation include: tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00809783?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00809783's enrollment target sits among peer trials
2,147 96th of 2000 higher than 1,905 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI